Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broking boss makes £2.6m profit

Mon, 02nd Nov 2009 16:30

Evolution chief executive Alex Snow has sold £5.2m of shares after being awarded 4.59m shares from two company option schemes after the vesting conditions for the shares were met. The Evolution Group Plc 2000 Executive Share Option Scheme issued 3.09m shares to Snow, Of these, 2.026m did not have any performance criteria, while the award of the rest was based on share price performance. These shares were acquired at 58.67p a share. The total cost was £1.81m. The other 1.5m shares were issued under the Evolution Group Plc 2001 Executive Share Option Scheme - following the achievement of share price performance criteria - and they cost 52.3p each. The total cost was £785,000. That means that Snow made a £2.6m profit on the share sales, which were at 163p a share. The share price is the highest it has been for more than three years. He retains 1.4m of the shares that he was awarded. This still leaves Snow with a higher percentage of the company. He owns 5.6m shares, which is equivalent to 2.42% of Evolution. Snow has taken up all the shares he had under option at the time of the 2008 annual report. Last week, the broker announced that its 2009 profits would be better than expected. Corporate activity has increased in the second half of the year. Funds under management have grown to £5bn at the end of September 2009. In April, Snow raised nearly £927,000 by selling shares at 114p each. That followed the exercise of options over 2m shares at 1p each - a total cost of £20,000. Snow said that the sale proceeds paid for the options and associated tax costs. That means that Snow has made more than £3.5m profit from share sales this year, while retaining 2.57m shares he has been awarded. Top Director BuysAccess Intelligence (ACC) Director name: Mr David LoweAmount purchased: 961,111 @ 4.70p Value: £45,172CLS Holdings (CLI) Director name: Mr Sten A MortstedtAmount purchased: 7,940 @ 443.00p Value: £35,174Jetion Solar Holdings (JHL) Director name: Mr Raymond WongAmount purchased: 30,000 @ 64.50p Value: £19,350Top Director SellsEvolution Group (EVG) Director name: Mr Alex SnowAmount sold: 3,191,565 @ 163.00p Value: £5,202,251Diageo (DGE) Director name: Mr Paul S WalshAmount sold: 99,000 @ 1,000.00p Value: £990,000
More News
20 Sep 2021 14:50

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

Read more
2 Sep 2021 11:56

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

Read more
13 Jul 2021 15:36

Evgen pleased with preclinical data on SFX-01

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vitro models of certain blood cancers on Tuesday.

Read more
13 Jul 2021 14:09

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

Read more
13 Jul 2021 11:25

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

Read more
13 Jul 2021 11:20

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

Read more
9 Jul 2021 11:51

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Read more
9 Jul 2021 10:52

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Read more
9 Jul 2021 10:33

Evgen 'surprised and disappointed' by findings in SFX-01 trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the results of the interim safety and futility assessment readout of the first 100 patients treated in the 'STAR' Covid-19 trial of its lead asset, 'SFX-01', on Friday.

Read more
6 Jul 2021 16:10

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
15 Jun 2021 14:42

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

Read more
14 Jun 2021 13:19

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

Read more
14 Jun 2021 11:00

Evgen upbeat on new data on potential breast cancer treatment

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC) patients who had become resistant to CDK4/6 inhibitors.

Read more
26 Apr 2021 13:02

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

Read more
7 Apr 2021 16:22

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.